Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour
NCT01058616
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
14
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer With Transdermal Accessible Tumour
Interventions
DRUG:
LTX-315 (Oncopore™)
Sponsor
Lytix Biopharma AS
Collaborators
[object Object]
[object Object]